Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma

被引:49
|
作者
Krieger, D. A. [1 ]
Hudgins, P. A. [2 ]
Nayak, G. K. [7 ]
Baugnon, K. L. [2 ]
Corey, A. S. [2 ]
Patel, M. R. [3 ]
Beitler, J. J. [3 ,4 ,5 ]
Saba, N. F. [5 ]
Liu, Y. [6 ]
Aiken, A. H. [2 ]
机构
[1] Hackensack Univ Med Ctr, Dept Radiol, Hackensack, NJ USA
[2] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, Atlanta, GA USA
[3] Emory Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Atlanta, GA USA
[4] Emory Univ, Sch Med, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA USA
[5] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
[6] Emory Univ, Sch Med, Dept Biostat, Winship Canc Inst, Atlanta, GA USA
[7] NYU, Dept Radiol, Sch Med, 560 1st Ave, New York, NY 10016 USA
关键词
SURVEILLANCE PET/CT; CANCER; UTILITY;
D O I
10.3174/ajnr.A5157
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND PURPOSE: The Head and Neck Imaging Reporting and Data System (NI-RADS) surveillance template for head and neck cancer includes a numeric assessment of suspicion for recurrence (1-4) for the primary site and neck. Category 1 indicates no evidence of recurrence; category 2, low suspicion of recurrence; category 3, high suspicion of recurrence; and category 4, known recurrence. Our purpose was to evaluate the performance of the NI-RADS scoring system to predict local and regional disease recurrence or persistence. MATERIALS AND METHODS: This study was classified as a quality-improvement project by the institutional review board. A retrospective database search yielded 500 consecutive cases interpreted using the NI-RADS template. Cases without a numeric score, non-squamous cell carcinoma primary tumors, and primary squamous cell carcinoma outside the head and neck were excluded. The electronic medical record was reviewed to determine the subsequent management, pathology results, and outcome of clinical and radiologic follow-up. RESULTS: A total of 318 scans and 618 targets (314 primary targets and 304 nodal targets) met the inclusion criteria. Among the 618 targets, 85.4% were scored NI-RADS 1; 9.4% were scored NI-RADS 2; and 5.2% were scored NI-RADS 3. The rates of positive disease were 3.79%, 17.2%, and 59.4% for each NI-RADS category, respectively. Univariate association analysis demonstrated a strong association between the NI-RADS score and ultimate disease recurrence, with P < .001 for primary and regional sites. CONCLUSIONS: The baseline performance of NI-RADS was good, demonstrating significant discrimination among the categories 1-3 for predicting disease.
引用
收藏
页码:1193 / 1199
页数:7
相关论文
共 50 条
  • [1] NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma
    Baugnon, Kristen L.
    NEUROIMAGING CLINICS OF NORTH AMERICA, 2022, 32 (01) : 1 - 18
  • [2] Interreader reproducibility of the Neck Imaging Reporting and Data system (NI-RADS) lexicon for the detection of residual/recurrent disease in treated head and neck squamous cell carcinoma (HNSCC)
    Abdelaziz, Tougan Taha
    Abdel Razk, Ahmed Abdel Khalek
    Ashour, Manar Maamoun Mohamed
    Abdelrahman, Ahmed S.
    CANCER IMAGING, 2020, 20 (01)
  • [3] Diagnostic accuracy of NI-RADS for prediction of head and neck squamous cell carcinoma: a systematic review and meta-analysis
    Li, Wei
    Sun, Yuan
    Shang, Wenwen
    Xu, Haibing
    Zhang, Hui
    Lu, Feng
    RADIOLOGIA MEDICA, 2024, 129 (01): : 70 - 79
  • [4] Interrater Reliability of NI-RADS on Posttreatment PET/Contrast-enhanced CT Scans in Head and Neck Squamous Cell Carcinoma
    Hsu, Derek
    Rath, Tanya J.
    Branstetter, Barton F.
    Anzai, Yoshimi
    Phillips, C. Douglas
    Juliano, Amy F.
    Mosier, Kristine M.
    Bazylewicz, Michael P.
    Poliashenko, Stan M.
    Kulzer, Matthew H.
    Rhyner, Patricia A.
    Risk, Benjamin
    Wiggins, Richard H.
    Aiken, Ashley H.
    RADIOLOGY-IMAGING CANCER, 2021, 3 (03):
  • [5] Negative Predictive Value of NI-RADS Category 2 in the First Posttreatment FDG-PET/CT in Head and Neck Squamous Cell Carcinoma
    Wangaryattawanich, P.
    Branstetter, B. F.
    Hughes, M.
    Clump, D. A., II
    Heron, D. E.
    Rath, T. J.
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2018, 39 (10) : 1884 - 1888
  • [6] Comparison of salvage surgery for recurrent or residual head and neck squamous cell carcinoma
    Maruo, Takashi
    Zenda, Sadamoto
    Shinozaki, Takeshi
    Tomioka, Toshifumi
    Okano, Wataru
    Sakuraba, Minoru
    Tahara, Makoto
    Hayashi, Ryuichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (03) : 288 - 295
  • [7] Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
    Lasniska, Izabela
    Kolenda, Tomasz
    Teresiak, Anna
    Lamperska, Katarzyna M.
    Galus, Lukasz
    Mackiewicz, Jacek
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (03) : 290 - 303
  • [8] Initial staging examinations for head and neck squamous cell carcinoma: are they appropriate?
    Andrle, J.
    Schartinger, V. H.
    Schwentner, I.
    Deibl, M.
    Sprinzl, G. M.
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2009, 123 (08) : 885 - 888
  • [9] Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck
    Nemunaitis, John
    Clayman, Gary
    Agarwala, Sanjiv S.
    Hrushesky, William
    Wells, James R.
    Moore, Charles
    Hamm, John
    Yoo, George
    Baselga, Jose
    Murphy, Barbara A.
    Menander, Kerstin A.
    Licato, Laura L.
    Chada, Sunil
    Gibbons, Robert D.
    Olivier, Magali
    Hainaut, Pierre
    Roth, Jack A.
    Sobol, Robert E.
    Goodwin, W. Jarrard
    CLINICAL CANCER RESEARCH, 2009, 15 (24) : 7719 - 7725
  • [10] Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma
    Desilets, Antoine
    Soulieres, Denis
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (08) : 927 - 933